Trial reportJournal of hypertension2026
Pharmacogenomics-guided personalized therapy for hypertension: a multicenter randomized trial.
Trial report in Journal of hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveUncontrolled hypertension presents a substantial challenge to healthcare systems. This study was designed to investigate whether pharmacogenomics-guided personalized medication regimens could enhance blood pressure control and medication optimization in patients with hypertension compared to conventional management approaches.
methodsIn this multicenter, single-blind, prospective, randomized controlled trial, 776 hypertensive outpatients were enrolled and allocated to either a personalized medication group or a control group across eight participating hospitals. All patients received 4 weeks of standardized hypertension management, followed by a first follow-up. Subsequently, the personalized medication group adjusted antihypertensive therapy according to seven predefined pharmacogenetic polymorphisms, while the control group continued standard treatment. After an additional 4 weeks, a second follow-up was performed to reassess blood pressure, medication utilization, and adverse events.
resultsThe personalized medication group achieved a notably higher blood pressure control rate compared to the control group, with female patients demonstrating particularly pronounced benefits. Additionally, the personalized medication group required fewer antihypertensive medications. The incidence of adverse events, including reactions to angiotensin II receptor blockers, angiotensin-converting enzyme inhibitors, β-blockers, calcium channel blockers, and diuretics, did not differ significantly between groups. Multifactorial analysis indicated that personalized medication significantly lowered the risk of uncontrolled blood pressure. Furthermore, the CYP2C9*3 gene variant was associated with uncontrolled blood pressure after standardized treatment.
conclusionPharmacogenomics-guided personalized medication regimens significantly improved blood pressure control and optimized medication usage without increasing adverse events. These findings highlight the potential of pharmacogenomics to guide precision therapy in hypertension management.
trial registrationChinese Clinical Trial Registry (ChiCTR2200057507). Registered 14 March 2022.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.